Privately-owned UK biotech Cell Medica has named Chris Nowers (pictured above) its new chief executive after its founder and former leader Gregg Sando stepped down.
Cell Medica is focused on personalized cancer immunotherapies and it is in that field that Mr Nowers has been working with Kite Pharma, a US company that was acquired by biotech giant Gilead Sciences (Nasdaq: GILD) last year.
"His experience in the commercialization of oncology programs is an excellent fit for the company’s ambitions"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze